NCT02179671View on ClinicalTrials.gov

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 25, 2014

Primary Completion Date

June 11, 2016

Study Completion Date

June 11, 2016

Conditions
Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)
Interventions
DRUG

Gefitinib

Gefitinib once daily followed by MEDI4736

DRUG

AZD9291

AZD9291 once daily followed by MEDI4736

DRUG

Selumetinib+Docetaxel

Selumetinib twice daily + docetaxel, followed by MEDI4736

DRUG

Tremelimumab

Tremelimumab every 4 weeks followed by MEDI4736

Trial Locations (10)

11501

Research Site, Mineola

20007

Research Site, Washington D.C.

28078

Research Site, Huntersville

30060

Research Site, Marietta

30912

Research Site, Augusta

41101

Research Site, Ashland

63110

Research Site, St Louis

85338

Research Site, Goodyear

98405

Research Site, Tacoma

99208-1129

Research Site, Spokane

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

Quintiles, Inc.

INDUSTRY

lead

AstraZeneca

INDUSTRY